Revance's stock falls 35% after FDA says it won't approve the company's frown-line injection

Dow Jones2021-10-18

Shares of Revance Therapeutics Inc. tumbled 34.65% in premarket trading on Monday after the company said Friday that the Food and Drug Administration had declined to approve Revance's application for a frown-line treatment.

The FDA issued a complete response letter that the company received Oct. 15, citing issues with Revance's manufacturing facilities. Revance said it plans to address those concerns.

Revance's stock is down 19.9% for the year, while the broader S&P 500 is up 19.0%.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

发表看法
3